Introduction
Breast cancer is the most common malignant disease affecting women worldwide. Recent statistics indicate that breast cancer is estimated to account for 30% of all new cancer diagnoses in women [
1]. Despite recent advances in breast cancer diagnosis and therapeutic techniques such as hormonal and target therapy, chemotherapy, and radiotherapy, patients under remission may still experience breast cancer relapse and spread [
2,
3]. Therefore, improving our understanding of the biology of cancer metastasis may lead to the discovery of more effective strategies for improving the prognosis and treatment of advanced breast cancer.
Metastasis is the major cause of almost all breast cancer deaths. Secondary growth in breast cancer primarily occurs in the lymph nodes, bones, liver, lungs, and brain [
4]. A remarkable feature of this multi-step and highly-organized cell biological process is the variation in metastatic organ-specific tropism depending on the tumor type [
5,
6]. One of the reasons for organ-specific tropism of cancer cells is the formation of a permissive microenvironment, known as the metastatic niche, in target organs. Myeloid-derived suppressor cells (MDSCs) have been proven to play a prominent role in the establishment of the metastatic microenvironments [
7,
8]. MDSCs are a heterogeneous population of immune cells that are myeloid origin precursors and relatively immature. Currently, MDSCs are divided into two distinct subsets, polymorphonuclear (PMN)- or granulocytic (G)-MDSC, and monocytic (M)-MDSC [
9]. G-MDSCs (CD11b
+Ly6C
int/loLy6G
+) share many phenotypic and functional features of neutrophils, whereas M-MDSCs (CD111b
+Ly6C
+Ly6G
−) are related to monocytes [
10,
11]. The granulocytic nature of CD11b
+Gr-1
+ cells has been detected in the lung tissue of mice with mammary adenocarcinoma [
12]. Growing evidence supports the hypothesis that MDSCs exert their pro-tumorigenic effects by suppressing T and B cell functions and promoting tumor angiogenesis, proliferation, survival, and metastasis [
13]. However, it remains unclear why and how MDSCs accumulate in the lungs, creating a permissive microenvironment for metastasizing breast cancer cells.
Chemokines, a superfamily of small chemotactic cytokines with the ability to bind to G-protein-coupled receptors, play a critical role in the recruitment of various immune cells to specific tissues, in a variety of physiological and pathological conditions [
14,
15]. Chemokine (C-X-C motif) ligand 17 (CXCL17) is a novel 119 amino acid CXC chemokine, which has been reported to express in colon and breast cancers and promotes cancer progression [
16‐
18]. CXCL17 has been identified as an independent prognostic factor for overall survival and progression-free survival for patients with hepatocellular carcinoma, since it is negatively correlated with CD4
+ T cell accumulation, but positively regulates CD68
+ macrophage infiltration [
19]. In addition, ectopic expression of CXCL17 increases tumorigenesis and cancer growth by recruitment of CD11b
+Gr-1
highF4/80
− cells in the primary site of colon cancer [
18]. Herein, we describe the pathogenic role of CXCL17 in the formation of a lung metastatic niche in the case of breast cancer. In addition, CXCL17 levels have been correlated with breast cancer metastases among patients with breast cancer. Therefore, we propose that the evaluated expression of CXCL17 in breast cells might play a pivotal role in the MDSC-driven lung shaping by platelet-derived growth factor-BB (PDGF-BB) that contributes to lung metastasis.
Materials and methods
Cell lines and reagents
Human breast cancer MDA-MB-231, murine breast cancer 4T1, and endothelial C166 cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). MDA-MB-231-RFP-Luciferase cells were obtained from GenTarget Inc. All cell lines were assessed for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD) every 6 months. 4T1 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS) and antibiotics. MDA-MB-231 and MDA-MB-231-RFP-Luc cells were cultured in Leibovitz’s L-15 medium supplemented with 10% FBS (Life Technologies, Grand Island, NY). C166 cells were cultured in with DMEM medium supplemented with 10% FBS. Recombinant mouse (rm) and human (rh) CXCL17 was obtained from R&D Systems (Minneapolis, MN, USA). CID 2745687 and DMPQ dihydrocloride (5,7-Dimethoxy-3-(4-pyridinyl)quinoline dihydrochloride, DMPQ 2HCl) were obtained from Torcis (Minneapolis, MN, USA). PDGF-BB was obtained from ProSpec (Ness Ziona, Israel).
Mouse studies
All mice procedures were conducted and approved in accordance with the Institutional Animal Care and Use Committee at Kaohsiung Medical University. BALB/c mice (female, 5-week-old) were treated with rmCXCL17 for 14 days (1 μg/mouse, 2 times/week, n = 6 per group) by intra-tracheal route, and 4T1 cells (500,000 cells per fat pad) were implanted into the mammary fat pads and allowed to spontaneously metastasize to the lung for 24 days. For lung metastasis of a human breast cancer model, athymic nude mice (6-week-old females, n = 6 per group) were treated with rmCXCL17 protein (1 μg/mouse, 2 times/week) for 14 days, then human MDA-MB-231 or MDA-MB-231-RFP-Luc cells were injected via the tail vein for the indicated times (90 days for lung metastasis and 48 h for extravasation). Tumors in primary sites and the lungs were harvested after the indicated times, fixed and embedded in paraffin, sectioned, and immunostained with antibodies against CD31 antibodies (Catalog #ab28364, dilution 1:100). All lung nodules in both lung lobes were calculated and tumor nodules occurring in the same site of sequential sections were only calculated once. Quantitative studies of stained sections were performed independently by three researchers in blinded fashion. The total number of tumor nodules per whole lung lobe was counted and averaged among the animals of each group. Quantitative analyses of CD31 staining were performed with the image analysis program ImageJ. Assays were carried out three times, and three random fields per sample were analyzed in five high-power fields (100 magnification [10 objective and 10 ocular]). For L4T1 generation, 4T1 cells were transplanted into BALB/c mice from mammary fat pads. The animals were then sacrificed on day 24, and the 4T1 cells in the lungs were isolated by mincing, collagenase type I digestion, and filtering. 4T1 cells were cultured in a growth medium containing 10% fetal bovine serum and 1% penicillin–streptomycin and expanded for second-round transplantation. The 4T1 sub-line of transplantation was designated as L4T1. For MDSC depletion studies, mice were treated with isotype or anti-Gr-1 antibody (Bio X Cell, West Lebanon, NH) at 0.25 mg/mouse intraperitoneal injections every 4th day, and 4T1 cells were injected via tail vein into the mice (six per group). The control group received intraperitoneal injections of purified rat immunoglobulins. For PDGF receptor inhibition studies, mice were treated with imatinib mesylate (Sigma-Aldrich) (100 mg/kg) by oral gavage three times weekly, and 4T1 cells were transplanted into mice from mammary fat pads (n = 6 per group). The control group received oral gavage of vehicle control (10% ethanol and 90% corn oil).
Isolation of CD11b+F4/80+, CD11b+Gr-1+, and CD11b+Gr-1− cells from lungs of mice
Murine lung tissue was dispersed using 2% collagenase A and 0.75% DNase I (Roche Diagnostics GmbH, Germany) in RPMI1640 medium supplemented with 10% FBS at 20 °C for 1 h. CD11b+ F4/80+ cells were isolated from the lungs of mice by magnetic cell sorting using mouse CD11b and F4/80 antibodies conjugated with magnetic beads. CD11b+Gr-1+ and CD11b+Gr-1− cells were isolated using MDSC Isolation Kit (MACS, Miltenyi Biotec) according to the manufacturer’s instructions.
Microarray
Microarray experiment procedures were carried out following the manufacturer’s protocols. Total RNA was amplified by an Agilent Quick Amp Labeling Kit (Agilent Technologies, USA). Cy-labeled cRNA (0.3 μg) was cleaved to an average size of about 50–100 nucleotides by incubation with fragmentation buffer (Agilent Technologies) at 60 °C for 30 min. Equal Cy-labeled cRNA was pooled and hybridized to Agilent SurePrint G3 Mouse GE 8x60K Microarray (Agilent Technologies, USA), then scanned by an Agilent microarray scanner (Agilent) at 535 nm for Cy3 and 625 nm for Cy5. Scanned images were analyzed by Feature Extraction software 10.5 (Agilent Technologies), and image analysis and normalization software was used to quantify signal and background intensity for each feature, which substantially normalized the data using the rank-consistency-filtering LOWESS method.
Measurement of secreted factors
The levels of angiogenic factors were determined by Luminex Assays (R&D Systems). CXCL17 levels were assessed by human or mouse CXCL17 ELISA kits (Cusabio Biotech, Wuhan, China).
C166 (4 × 105 cells/well) were then plated on reduced growth factor Matrigel (200 μL/well) (BD Biosciences, San Josè, CA) in 48-well plates and treated with conditioned medium (CM) (50%) of CD11b+Gr-1+ MDSCs isolated from normal mice for 3 h. Photographs were taken using a Nikon fluorescence microscope. The total tube area was quantified as mean pixel density obtained from image analysis of three random microscopic fields using ImageJ software.
Migration, transendothelial migration, and colony formation
Cell migration assays were conducted using the 3- or 8-μm inserts (EMD Millipore). PKH26-labeled CD11b+Gr-1+ or 4T1 cells (1 × 105 cells/well) were seeded onto inserts, and CXCL17 (1 or 10 ng/ml in RPMI1640 medium containing 1% FBS) or CMs of CD11b+Gr-1+ MDSCs were added to the bottom wells for 24 h as chemoattractant. Migratory cells were counted using a fluorescence microscope. For transendothelial migration, C166 were seeded onto inserts with polyester membranes of 3 (for MDSCs) or 8 μm (for 4T1 cells) pore size (EMD Millipore) and cultured for 2 days to allow a confluent monolayer to form. PKH26-labled CD11b+Gr-1+ MDSCs or 4T1 cells were seeded onto C166-coated inserts for 24 h. CMs of CD11b+Gr-1+ MDSCs isolated from normal or 4T1-bearing mice were placed at the bottom wells to be acted as chemoattractant, and the migratory cells were made visible using a fluorescence microscope. For colony formation, 4T1 cells (1 × 103) were seeded into a 60-mm dish and then treated with CM of CD11b+Gr-1+ MDSCs isolated from normal or 4T1-bearing mice (50%). After 7 days, the colonies were fixed by formalin (1%), then stained by crystal violet.
CXCL17 expression and Kaplan-Meier analyses of breast cancer patients
The SurvExpress contain 189 (Sotiriou Van de Vijver Breast GSE2990) and 327 (Kao Hung Breasr GSE20685) breast cancer patients with follow-up time intervals [
20]. The data were used to estimate the prognostic significance of the
CXCL17 transcript for metastasis curve, while Kaplan-Meier plotter database was used to evaluate distant metastasis-free survival [
21].
Statistical analyses
Data were expressed as mean ± standard deviation (SD) or standard error of mean (SEM). Two treatment groups were compared by Student’s t test. Multiple group comparisons were performed by two-way analysis of variance with Tukey’s post hoc test. Metastatic quantifications were assessed with a Mann-Whitney U test. GraphPad Prism version 7.04 (GraphPad Inc., La Jolla, CA) was used for statistical analyses. Results were considered statistically significant when P < 0.05.
Discussion
Increasing evidence indicates that metastatic sites do not support survival of disseminated cancer cells, but are also actively and specifically primed by the primary tumor before cells arrive at the metastatic site [
5,
23]. Characterization and recognition of primary cancer-derived factors that trigger vascular disruption and immune responses in the formation of lung metastatic niche in breast cancer is an important but as yet poorly defined process. In this study, we provide data that reveals the novel functions of CXCL17 on the establishment of supportive lung metastatic niches for cancer by recruiting CD11b
+Gr-1
+ MDSCs, which in turn support angiogenesis, cancer extravasation, and survival in new microenvironments.
Previous studies have indicated that primary cancer cells release soluble factors that either directly recruit immune cells to the metastatic niche or cooperate with niche cells to establish a metastatic environment [
28,
29]. In addition, it has been reported that the primary cancer or immune cells, which would then selectively prepare the lung metastatic niche and promote cancer cells spreading to here via making the cytokine, whereas alternatively another view indicates that the cytokine is selectively made in that niche after the cancer cells have already become established [
28,
30‐
32]. A number of studies indicate that CXCL17 can directly recruit immunosuppressive cells, such as neutrophils, macrophages, and MDSCs, to inflammatory sites and tumor tissues [
18,
22,
33]. GPR35 (or CXCR8) has been reported to be the receptor of CXCL17, expressed in various immune cells, including neutrophils, T cells, monocytes, and dendritic cells, with lower expression in B cells, eosinophils, basophils, and platelets [
34,
35]. In our current study, we found that CXCL17 is specifically expressed in 4T1 tumors that have metastasized to the lungs by comparing gene profiles of 4T1 tumors, which have spread to lymph glands, the intestines, and the liver. In addition, the administration of CXCL17 is favored for metastasis of breast cancer, whereas knockdown of CXCL17 prevents spontaneous spreading of breast cancer from primary site. Moreover, CXCL17 increased infiltration of CD11b
+GR-1
+ MDSCs into the lung metastatic niche by enhancing basal motility and transendothelial migration in a GPR35-dependent manner. This conclusion is supported by examination of the public dataset, which indicates that CXCL17 expression is negatively correlated with the distant metastasis-free survival. These results reveal that CXCL17 is involved in both lung pre-metastatic niches before cancer cell arrival and metastatic microenvironment establishment. Therefore, CXCL17 could be used as a prognostic tool as well as a therapeutic target in lung metastasis of breast cancer.
MDSCs are necessary constituents of the metastatic niches, where they play tumor-promoting, immune-suppressive, or both roles [
36,
37]. Phenotypic analysis of MDSCs accumulated in the lungs of mice bearing mammary adenocarcinoma showed that CD11b
+Gr-1
+ MDSCs, but not CD11b
+Gr-1
− MDSCs and macrophages, are recruited in metastatic lungs, indicating that CD11b
+Gr-1
+ MDSCs are major, specific constituents which contribute to metastatic niche formation in the lungs [
12]. The granulocytic nature of CD11b
+Gr-1
+ MDSCs is immunosuppressive, directly inhibiting T cell function, and other myeloid and NK cells [
38,
39]. Furthermore, CD11b
+Gr-1
+ cells increase angiogenesis in organ-specific metastatic niches to enhance tumor metastasis by BV8 expression [
40,
41]. Our study confirmed that CXCL17 increased the accumulation of CD11b
+Gr-1
+ MDSCs, which in turn increased angiogenesis in pulmonary metastatic niches. CXCL17-induced CD11b
+Gr-1
+ MDSCs also supported cancer cell extravasation and survival in the lungs of mice. Moreover, depletion of CD11b
+Gr-1
+ MDSCs reduced angiogenesis and cancer colonization in lungs, indicating they are responsible for multiple steps of the lung metastatic cascade in breast cancer. Our work reveals a novel role of CD11b
+Gr-1
+ MDSCs in lung metastasis of breast cancer, without the regulatory activity on innate and acquired immune cells.
It is well established that PDGF-BB contributes to cancer progression by promoting cancer growth, migration, and tumor angiogenesis [
42,
43]. PDGF-BB triggers the invasive phenotypes of cancer cells by Src signaling, including cell adhesion, migration, and invasion [
26,
43]. PDGF-BB has also been shown to increase metastasis of cancer cells into the lungs and bone [
44,
45]. Cancer cells, cancer-associated fibroblasts, and lymphatic and vascular endothelial cells have been implicated as being major sources of high levels of PDGF-BB in breast cancer [
46]. In this study, we found that CD11b
+Gr-1
+ MDSCs express higher levels of PDGF-BB, which not only increases angiogenesis in metastatic lungs, but also enhances incoming metastatic tumor cells’ migration from circulation into the lungs and growth of secondary cancers therein. Furthermore, inhibition of PDGF receptor decreases lung metastasis in mice, representing the fact that PDGF-BB contributes to lung metastasis of breast cancer. Therefore, this current study verifies that PDGF-BB plays a critical role in CD11b
+Gr-1
+ MDSC-mediated breast cell retention in the lungs and, if targeted, may have potential therapeutic benefit to reduce lung metastasis of breast cancer.
The specific receptors that are evaluated in breast cancer in clinical practice are the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2-neu (HER2/neu) receptor [
47]. These receptors are both prognostic and predictive utilities for breast cancer patients treated with targeted therapy. Therefore, when metastasis is suspected, it is important to make a biopsy not only to check recurrent disease, but also to validate specific receptor levels. The expression of CXCL17 has been indicated as being positively correlated with ER status [
48]. The models including 4T1 and MDA-MB-231 breast cancer used in our study are triple-negative breast cancer; therefore, further study is required to clarify possible roles of ER, PR, or Her2/neu in the regulation of CXCL17 in breast cancer.